Ohnishi A, Ohsawa M, Yasunaga Y, Ijuin N, Sawada M, Yamamoto S, Aozasa K
Department of Pathology, Osaka University Medical School, Japan.
J Surg Oncol. 1996 Aug;62(4):245-8. doi: 10.1002/(SICI)1096-9098(199608)62:4<245::AID-JSO3>3.0.CO;2-6.
Occurrence of monocytoi B lymphocytes (MBL) in the lymph nodes of patients receiving preoperative chemotherapy for cancer was examined and compared to lymph nodes in controls who had not received chemotherapy. Number of patients receiving and not receiving preoperative chemotherapy were 3 and 10 cases in ovarian cancer, 7 and 11 in testicular cancer, and 22 and 8 in lung cancer, respectively. Chemotherapeutic agents for ovarian, testicular, and lung cancer consisted of cisplatin, Adriamycin, and cyclophosphamide; cisplatin, vinblastine, and bleomycin; and cisplatin, vindesin, and mitomycin, respectively. MBL were defined morphologically as having abundant pale cytoplasm with distinct cell borders and small nucleus. Immunohistochemistry revealed a B-cell nature of these cells, i.e., CD20+ and/or MB-1+ together with negative reactivity for antibodies for T lymphocytes (CD43, CD45RO, OPD4) and macrophages (KP-1, PGM-1). Monocytoid cells in two cases showed a positive reactivity for CD43 together with CD20. The occurrence rate of MBL in patients with ovarian, lung, and testicular cancer receiving and not receiving chemotherapy was 67% (2/3) and 10% (1/10), 59% (13/22) and 75% (6/8), and 43% (3/7) and 9% (1/11), respectively. The occurrence rate in the total patients receiving chemotherapy (56%) was significantly higher than for those not receiving chemotherapy (28%) (P < 0.05). These findings suggest that chemotherapy-induced depressed immune function is causative for the occurrence of MBL in the lymph nodes. MBL might be found more frequently in nodes from patients who have received chemotherapy in certain settings.
对接受癌症术前化疗患者的淋巴结中单核细胞样B淋巴细胞（MBL）的出现情况进行了检查，并与未接受化疗的对照组淋巴结进行了比较。接受和未接受术前化疗的卵巢癌患者分别为3例和10例，睾丸癌患者分别为7例和11例，肺癌患者分别为22例和8例。卵巢癌、睾丸癌和肺癌的化疗药物分别为顺铂、阿霉素和环磷酰胺；顺铂、长春碱和博来霉素；以及顺铂、长春地辛和丝裂霉素。MBL在形态学上被定义为具有丰富的淡染细胞质、明显的细胞边界和小细胞核。免疫组织化学显示这些细胞具有B细胞性质，即CD20+和/或MB-1+，同时对T淋巴细胞（CD43、CD45RO、OPD4）和巨噬细胞（KP-1、PGM-1）抗体呈阴性反应。2例中的单核细胞样细胞对CD43和CD20呈阳性反应。接受和未接受化疗的卵巢癌、肺癌和睾丸癌患者中MBL的发生率分别为67%（2/3）和10%（1/10）、59%（13/22）和75%（6/8）、43%（3/7）和9%（1/11）。接受化疗的所有患者的发生率（56%）显著高于未接受化疗的患者（28%）（P<0.05）。这些发现表明化疗诱导的免疫功能抑制是淋巴结中MBL出现的原因。在某些情况下，MBL可能在接受化疗患者的淋巴结中更频繁地被发现。
